| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0149-2918(00)83039-8 |
| P698 | PubMed publication ID | 11192132 |
| P2093 | author name string | Rosenzweig J | |
| Rendell M | |||
| Einhorn D | |||
| Schneider RL | |||
| Mathisen AL | |||
| Egan JW | |||
| P2860 | cites work | Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 |
| Rosiglitazone | Q33684266 | ||
| Pharmacologic therapy for type 2 diabetes mellitus | Q33716414 | ||
| Metabolic effects of metformin in non-insulin-dependent diabetes mellitus | Q34720764 | ||
| Management of dyslipidemia in adults with diabetes | Q41737048 | ||
| Plasma lipids and diabetes mellitus in an adult community | Q45222047 | ||
| Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. | Q51551544 | ||
| Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan. | Q51570683 | ||
| The homeostasis model in the San Antonio Heart Study. | Q51574832 | ||
| The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. | Q51599034 | ||
| Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. | Q51608165 | ||
| New drug overview. Pioglitazone hydrochloride | Q73477922 | ||
| Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas | Q77761950 | ||
| Mechanisms and clinical effects of thiazolidinediones | Q94447126 | ||
| P433 | issue | 12 | |
| P921 | main subject | metformin | Q19484 |
| placebo | Q269829 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 1395-1409 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group | |
| P478 | volume | 22 |
| Q35840613 | A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus |
| Q35987436 | A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. |
| Q36536205 | A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes |
| Q34479133 | A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus |
| Q37818234 | Add-on therapies to metformin for type 2 diabetes |
| Q46920661 | Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study |
| Q24547558 | Advances in diabetes for the millennium: drug therapy of type 2 diabetes |
| Q28512042 | Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone |
| Q37141727 | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus |
| Q36198965 | Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes |
| Q44981468 | Cardiovascular effects of rosiglitazone |
| Q36268105 | Cardiovascular effects of the thiazolidinediones. |
| Q35695439 | Clinical interest of PPARs ligands |
| Q37842472 | Combination lipid therapy in type 2 diabetes mellitus |
| Q44480350 | Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen |
| Q37453128 | Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study |
| Q49193708 | Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin |
| Q35734015 | Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective |
| Q36480971 | Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. |
| Q35044470 | Counseling patients with type 2 diabetes and insulin resistance in the outpatient setting |
| Q35147057 | Current management strategies for coexisting diabetes mellitus and obesity |
| Q33723387 | Current therapeutic options in type 2 diabetes mellitus: a practical approach |
| Q37524006 | Diabetes medications and body weight |
| Q35592329 | Diabetes mellitus and pharmacological therapy |
| Q34044879 | Differential sensitivities of the vascular K(ATP) channel to various PPAR activators |
| Q34580989 | Differentiating members of the thiazolidinedione class: a focus on efficacy |
| Q34580994 | Differentiating members of the thiazolidinedione class: a focus on safety |
| Q95817945 | Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update |
| Q33541294 | EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage |
| Q35614478 | Early combination therapy with a thiazolidinedione for the treatment of type 2 diabetes |
| Q44010115 | Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada |
| Q40358908 | Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial |
| Q38001085 | Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. |
| Q51381776 | Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. |
| Q43977158 | Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats |
| Q37000784 | Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels |
| Q35101116 | Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism |
| Q34599640 | Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records |
| Q42639421 | Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study |
| Q37794960 | Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. |
| Q44804875 | Ezetimibe: a novel option for lowering cholesterol |
| Q44896352 | Future targets in the treatment of type 2 diabetes |
| Q48457425 | Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. |
| Q44911243 | Heart, diabetes and glitazones |
| Q34458520 | Hepatotoxicity with thiazolidinediones: is it a class effect? |
| Q37071750 | Impact of therapeutic advances on hypoglycaemia in type 2 diabetes |
| Q37577126 | In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion |
| Q57688763 | Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease |
| Q34962291 | Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions |
| Q35557363 | Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes |
| Q53627172 | Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. |
| Q55069710 | Japanese Clinical Practice Guideline for Diabetes 2016. |
| Q46486537 | Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes |
| Q51489163 | Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. |
| Q45074002 | Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study |
| Q57026285 | Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q34592900 | Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study |
| Q56979722 | Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) |
| Q33216408 | Management of type 2 diabetes mellitus. Role of thiazolidinediones. |
| Q34716953 | Metabolic and additional vascular effects of thiazolidinediones. |
| Q34110707 | Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy |
| Q36423076 | Metformin and its clinical use: new insights for an old drug in clinical practice. |
| Q35641623 | Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy |
| Q78385000 | Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications |
| Q24187392 | Metformin monotherapy for type 2 diabetes mellitus |
| Q24246552 | Metformin monotherapy for type 2 diabetes mellitus |
| Q36283811 | Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents |
| Q37262966 | Metformin therapy and clinical uses |
| Q46920659 | Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy |
| Q38645273 | Metformin: clinical use in type 2 diabetes. |
| Q22241434 | Metformin: new understandings, new uses |
| Q35557366 | Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels |
| Q37727562 | Natural products for type II diabetes treatment |
| Q34660659 | New solutions for type 2 diabetes mellitus: the role of pioglitazone |
| Q35146648 | Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement |
| Q42607569 | Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug |
| Q34451776 | Oral therapies for diabetic hyperglycemia |
| Q49837836 | Palmitate-induced insulin resistance is attenuated by Pioglitazone and EGCG through reducing the gluconeogenic key enzymes expression in HepG2 cells |
| Q37577162 | Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes |
| Q34078900 | Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus. |
| Q37501666 | Peroxisome proliferator-activated receptor activating hypoglycemic effect of Gardenia jasminoides Ellis aqueous extract and improvement of insulin sensitivity in steroid induced insulin resistant rats. |
| Q36812788 | Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives |
| Q38350347 | Pharmacologic treatment of type 2 diabetes: oral medications |
| Q80391781 | Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy |
| Q64944872 | Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients. |
| Q34781949 | Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials |
| Q34449858 | Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy |
| Q46860919 | Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes |
| Q38650414 | Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. |
| Q34620604 | Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin |
| Q24244321 | Pioglitazone for type 2 diabetes mellitus |
| Q36139056 | Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review |
| Q41831875 | Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells |
| Q33204628 | Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data |
| Q44793906 | Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus |
| Q46817499 | Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes |
| Q38349512 | Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes |
| Q91875408 | Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies |
| Q46982956 | Pioglitazone. Review of its metabolic and systemic effects |
| Q79238106 | Pioglitazone/metformin |
| Q46883819 | Pioglitazone: a review of its use in type 2 diabetes mellitus |
| Q36569766 | Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects |
| Q36407383 | Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality |
| Q50988205 | Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. |
| Q51470458 | Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice. |
| Q35989381 | Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus |
| Q38076486 | Putting medications where they belong: practical advice for managing type 2 diabetes in clinical practice |
| Q36269666 | Rational drug design and PPAR agonists |
| Q34655587 | Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology |
| Q37167551 | Redefining the role of thiazolidinediones in the management of type 2 diabetes |
| Q37884618 | Review of approved pioglitazone combinations for type 2 diabetes |
| Q34620706 | Risk management in the treatment of type 2 diabetes with pioglitazone |
| Q24235718 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24240522 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q24244739 | Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus |
| Q33607697 | Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease |
| Q51490321 | Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. |
| Q35496591 | Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis |
| Q46193261 | Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus |
| Q45137278 | The place of thiazolidinediones in the treatment of type 2 diabetes |
| Q34660664 | The role of models within economic analysis: focus on type 2 diabetes mellitus. |
| Q35807254 | The role of sulphonylureas in the management of type 2 diabetes mellitus |
| Q37142138 | Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update |
| Q33827960 | Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes |
| Q37835820 | Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. |
| Q35162317 | Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence |
| Q35570243 | Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications |
| Q36283822 | Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. |
| Q36536290 | Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes |
| Q35557355 | Type 2 diabetes, cardiovascular risk, and the link to insulin resistance |
| Q34580999 | Where thiazolidinediones will fit. |
| Q80380593 | [Criteria and guidelines for combined therapy of type 2 diabetes. 2004 consensus document] |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
Search more.